STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 people with advanced head and neck cancer that has spread or come back after immunotherapy stopped working. One group gets standard chemo plus cetuximab, another gets chemo plus bevacizumab, and a third gets bevacizumab pl…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:48 UTC
-
Can a weekly chemo schedule be gentler yet just as effective for head and neck cancer?
Disease control TerminatedThis study compares two ways of giving the chemotherapy drug cisplatin along with radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see which schedule causes fewer side effects…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 26, 2026 10:47 UTC
-
New combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with head and neck cancer that has come back or spread. About 52 adults with incurable, advanced cancer will take part. The goal is to s…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Radiation boost may improve immunotherapy for advanced head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive the immunotherapy drug pembrolizumab plus chemotherapy. Half also get targeted radiation to their tumors. The goal is to see if adding radiation helps …
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:02 UTC